The Cutting Edge of
Precision Oncology

W're proud to partner with leading investigators at medical centers and biopharmaceutical companies to help transform how cancer is detected, treated, and managed.

Precision Medicine is Driving a New Era in Oncology Drug Development

Biopharma companies are at the forefront of introducing novel targeted therapies, redefining the therapeutic management of cancer. These treatments target the specific alterations or biomarkers of a patient, which can significantly extend progression-free survival compared to traditional chemotherapy or immunotherapy.1-7

More About Our Approach

Helping Pharmaceutical Companies Accelerate Precision Oncology Drug Development

From translational research to clinical development to commercialization, our Biopharma Solutions portfolio is at the cutting edge of products and best-in-class services. Our portfolio is designed to seamlessly meet your needs at each stage of research and development—all while refining focus and accelerating your outcomes.

Precision oncology is an essential part of the future of cancer care, which may one day even include targeted interventional therapies to help prevent disease progression at earlier stages.
Explore our Biopharma Solutions Offering

Pioneering Multiomic Approaches to Power Precision Oncology with Deeper Insights

Our portfolio of innovative solutions and best-in-class service spans:

Ensure your drug development programs stay ahead of the curve with Guardant Infinity™. A single assay tailored to fit your needs providing comprehensive genomic and epigenomic profiling insights for biomarker discovery and development of cancer therapies today and beyond.

Explore Guardant Infinity

Guardant360® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors.8-11 With broad medicare coverage, a growing pipeline of diagnostic claims and an expanding global network, Guardant Health can help accelerate clinical development and commercial success.

Explore Guardant360 CDx

Translational Research

Discover a new dimension of cancer with novel biomarkers to help understand dynamic tumor evolution and mechanisms of resistance.

Learn More

Clinical Development

Accelerate your clinical trials and optimize your CDx strategy with our comprehensive portfolio of tests and team of experts.

Learn More

Global Reach

Guardant Health has widespread clinical adoption in the U.S. and an expanding global footprint to help accelerate your commercial success.

Learn More

Real-World Evidence

Access our large multimodal clinical-genomic database to inform all phases of the drug development journey.

Learn More

Let’s Get Started

Contact our Biopharma Team to see how we can help you accelerate precision oncology and bring the next generation of cancer therapies to patients sooner.

Let's Connect
  1. Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of Oncology. 2019;30(7):1121-1126.
  2. Ramalingam SS, Gray JE, Ohe Y, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Annals of Oncology 2019;30(5):v851-v934.
  3. Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol. 2019;37(28):2518-2527.
  4. Camidge DR, Dziadziuszko R, Peters S, et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALKPositive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019;14(7):1233-1243.
  5. https://www.hcp.novartis.com/products/tafinlar-mekinist/metastatic-nsclc/efficacy/ Accessed online Jan. 10, 2020.
  6. Gadgeel SM, Garassino MC, Esteban E, et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. J Clin Oncol. 2019;37(suppl; abstr 9013).
  7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;14;355(24):2542-2550.
  8. Guardant360 CDx Technical Information. 2021.
  9. FDA News Release. 2020.
  10. FDA Recently Approved Devices. 2022.
  11. FDA Recently Approved Drugs. 2023.